Dr. Anticevic is a clinical neuroscientist working at the intersection of neuroscience, computation, and therapeutic development. He has dedicated his career to building quantitative measures of brain systems that improve decisions in CNS research and clinical translation. His research focus is centered on precision neuroimaging for CNS therapeutic development.

• Leads NAIO™, J&J's Neuroscience & AI-Optimized platform — a computational neuroimaging system that delivers quantitative, biomarker-driven measures to guide CNS therapeutic development.
• Founded and scaled Manifest Technologies from academic translation into a precision-neuroscience company, culminating in its acquisition by Johnson & Johnson in 2024.
• Directed Yale’s Psychiatry Division for Neurocognition, Neurocomputation, and Neurogenetics while leading a translational neuroimaging laboratory with international research impact, culminating in appointment as the Glenn H. Greenberg Associate Professor of Psychiatry, Psychology, and Neuroscience with Tenure.
• Published 180+ peer-reviewed papers, secured over $100M in research funding as PI/Co-PI, earned recognition as a Clarivate Highly Cited Researcher four consecutive years (2022-2025), and is a holder of two U.S. patents.